New Clinical Challenges in Hypertension Management: The 'Old Silent Killer' Is Alive and Well - 22/11/24
, Jared Greenwald c, John Dunn, BS d, Alexandra Matarazzo, BS d, Katerina Benson e, Panagiota Kitsantas, PhD d, Stacy Rubin, MD, FACP b| Funding: None. |
|
| Conflict of Interest: BRD serves as an independent scientist in an advisory role to investigators and sponsors as a member of 3 data monitoring committees for Amgen and 1 for BioBridge. CHH serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen and UBC, and to the United States Food and Drug Administration and Up to Date; receives royalties for authorship or editorship of 3 textbooks; has an investment management relationship with the West-Bacon Group within Truist Investment Services, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company. All other authors declare no conflicts of interest. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 137 - N° 12
P. 1154-1156 - décembre 2024 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
